Month: August 2022

– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 –– Phase 2 data for EDP2939 in psoriasis expected in 2H 2023 –– Management will host conference call at 7:30 a.m. ET – CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the second quarter 2022. Evelo’s SINTAX medicines platform and product candidates aim to disrupt how to treat the hundreds of millions of people globally who suffer with inflammatory diseases and lack access to effective treatments. This...

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for the quarter ended June 30, 2022. “We made meaningful strides across our strategic priorities in the second quarter and our pathway to profitability. We believe this commitment has materialized into strong revenue growth, sales pipeline expansion, and notably, margin improvement and sustainable cash burn,” said David Coman, Chief Executive Officer of Science 37. “We remain focused on leading the way as a pioneer in agile clinical trials with an eye on our objective of long-term profitability, and we are confident that Science 37 is well-positioned to deliver durable value for our shareholders.” Quarterly Financial HighlightsRevenue...

VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) — Titan Mining Corporation (TSX: TI) (“Titan” or the “Company“) today announces the results for the second quarter ended June 30, 2022. (All amounts are in U.S. dollars unless otherwise stated) “Titan’s Empire State Mines in New York has posted a record quarter with cash flow of $9.42 million from operations and production of 16.5 million payable pounds of zinc. Equally as important, this was accomplished with no lost time accidents,” said Don Taylor, President and Chief Executive Officer of Titan. Q2 2022 HIGHLIGHTS:$9.42 million cash flow from operations including net income of $5.9 million or $0.04 per share. Record zinc production totaling 16.5 million payable pounds and sales of 15.0 million pounds of zinc during the quarter; both records since the mine...

Q2 2022 Revenues, Gross Margin and EPS are in line with Updated Guidance on June 20, 2022Company Q3 2022 Guidance: Revenues to Decrease 35% to 39% QoQ, Non-IFRS Gross Margin is Expected to be 35.5% to 37.5%, Non-IFRS Profit per Diluted ADS to be around 11.6 Cents to 15.6 CentsQ2 2022 revenues was $312.6M, a decrease of 24.3% QoQ. Q2 GM reached 43.6% Q2 2022 non-IFRS after-tax profit was $76.8M, or 43.9 cents per diluted ADS, compared to $121.9M, or 69.7 cents last quarter Company’s Q3 2022 revenues to decrease 35% to 39% QoQ. Non-IFRS GM around 35.5% to 37.5%. Non-IFRS profit attributable to shareholders in the range of 11.6 to 15.6 cents per fully diluted ADS Himax believes its inventory will peak in Q3 Company’s automotive IC business now is the largest revenue contributor, set to represent over 35% of total sales in Q3. Himax expects...

Operating income for the second quarter increased by 16% year over year to a record second quarter result of $14.7 million; Non-GAAP operating income for the second quarter increased by 10% year over year to a record second quarter result of $17.6 million OR YEHUDA, Israel, Aug. 11, 2022 (GLOBE NEWSWIRE) — Magic Software Enterprises Ltd. (NASDAQ and TASE: MGIC), a global provider of IT consulting services and end-to-end integration and application development platforms solutions, announced today its financial results for the second quarter ended June 30, 2022. Summary Results for the Second Quarter 2022 (USD in millions, except per share data)                  GAAP     Non-GAAP    Q2 2022 Q2 2021 % Change     Q2 2022 Q2 2021 % ChangeRevenues $ 137.0   $ 119.2   15.0 %   $ 137.0   $ 119.2   15.0 %Gross Profit $ 36.6   $ 32.8   11.6 %   $ 38.2   $ 34.4   10.8 %Gross...

August 11th2022 Q2 2022 Interim Report and Investor Conference Call Announcement Welltec® will disclose its Q2 2022 Interim Report and will discuss the results during an investor conference call to be held Thursday, August 18th, 2022, at 5 pm CEST. The conference call will be available only to current and prospective bond holders, broker dealers, and securities analysts, and can be accessed by dialing in a few minutes before the start and informing the operator that you would like to participate in Welltec’s investor conference call. Relevant dial-in details and conference ID can be obtained by contacting Mads Brixtofte Rasmussen mbrasmussen@welltec.com and registering for the call. Registration will not be possible once the investor conference has started. The Q2 2022 Interim Report will be made available in the “Investor Room” on Welltec’s...